Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Britain Courts Anthropic Amid US Defense Department Dispute 
ST. HELIER, Jersey, Sept. 30, 2016 -- Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2016 on Wednesday, Nov. 2, 2016, before the open of U.S.-based financial markets. Novocure management will host a conference call and webcast to discuss its financial results for the three and six months ended Sept. 30, 2016, at 8 a.m. EDT on Wednesday, Nov. 2, 2016.
The conference call can be accessed by dialing 877-726-5929 for domestic callers and 530-379-4648 for international callers, using the conference ID 76871474. The webcast can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investors, and will be available for replay for at least 14 days following the call.
About Novocure
Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
Media and Investor Contact: Ashley Cordova 212-767-7558 [email protected]
